- Home
- TSI vs NGNE Comparison
TSI vs NGNE Comparison
Compare TSI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- NGNE
- Stock Information
- Founded
- TSI 1987
- NGNE 2003
- Country
- TSI United States
- NGNE United States
- Employees
- TSI N/A
- NGNE N/A
- Industry
- TSI Investment Managers
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- NGNE Health Care
- Exchange
- TSI Nasdaq
- NGNE Nasdaq
- Market Cap
- TSI 234.6M
- NGNE 251.9M
- IPO Year
- TSI N/A
- NGNE N/A
- Fundamental
- Price
- TSI $4.90
- NGNE $17.86
- Analyst Decision
- TSI
- NGNE Strong Buy
- Analyst Count
- TSI 0
- NGNE 7
- Target Price
- TSI N/A
- NGNE $41.86
- AVG Volume (30 Days)
- TSI 106.8K
- NGNE 183.6K
- Earning Date
- TSI 01-01-0001
- NGNE 08-08-2025
- Dividend Yield
- TSI 7.46%
- NGNE N/A
- EPS Growth
- TSI N/A
- NGNE N/A
- EPS
- TSI N/A
- NGNE N/A
- Revenue
- TSI N/A
- NGNE $925,000.00
- Revenue This Year
- TSI N/A
- NGNE N/A
- Revenue Next Year
- TSI N/A
- NGNE N/A
- P/E Ratio
- TSI N/A
- NGNE N/A
- Revenue Growth
- TSI N/A
- NGNE N/A
- 52 Week Low
- TSI $4.48
- NGNE $6.88
- 52 Week High
- TSI $4.87
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- TSI 29.71
- NGNE 48.91
- Support Level
- TSI $4.90
- NGNE $18.22
- Resistance Level
- TSI $4.94
- NGNE $21.43
- Average True Range (ATR)
- TSI 0.04
- NGNE 2.15
- MACD
- TSI -0.01
- NGNE -0.45
- Stochastic Oscillator
- TSI 0.00
- NGNE 19.98
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.